The documented research dose is ~2.33 mg of total blend per administration, which for a 70 mg vial reconstituted in 3 mL equals 0.10 mL, or 10 units on a U-100 syringe
However, it can also be given slowly intravenously or subcutaneously (injected into a vein or under the skin)
Alternativ kann das BPC-157 Pflaster aber auch direkt an der betroffenen Stelle eingesetzt werden beispielsweise an der Sehne, um die heilungsfrdernde Wirkung lokal auszuben
Metabolic adaptations: Rapid weight loss triggers metabolic adaptations including reduced muscle protein synthesis rates
The clinical thinking: for lean or sensitive patients, we often do not want weight suppression
Although several laboratory and animal studies suggest potential regenerative effects, there are scant high-quality randomized controlled human trials demonstrating its safety or efficacy